Product Information
Registration Status: ActiveSIN09554P
MOBIC TABLET 7.5mg is approved to be sold in Singapore with effective from 1997-11-28. It is marketed by BOEHRINGER INGELHEIM SINGAPORE PTE LTD, with the registration number of SIN09554P.
This product contains Meloxicam 7.5mg in the form of TABLET. It is approved for ORAL use.
This product is manufactured by BOEHRINGER INGELHEIM PHARMA GMBH & CO KG in GREECE, andBoehringer Ingelheim Ellas A.E. in GERMANY.
It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.
Product Reference
Important Note: For generic product, the SPC/PIL provided may not be brand specific.
{{/items}} {{^items}}Description
Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve the symptoms of arthritis, primary dysmenorrhea, fever; and as an analgesic, especially where there is an inflammatory component. It is closely related to piroxicam. In Europe it is marketed under the brand names Movalis, Melox, and Recoxa. In North America it is generally marketed under the brand name Mobic. In Latin America, the drug is marketed as Tenaron.
Indication
For symptomatic treatment of arthritis and osteoarthritis.
Mechanism of Action
Anti-inflammatory effects of meloxicam are believed to be due to inhibition of prostaglandin synthetase (cylooxygenase), leading to the inhibition of prostaglandin synthesis. As prostaglandins sensitize pain receptors, inhibition of their synthesis may be associated with the analgesic and antipyretic effects of meloxicam.
Pharmacokinetics
- Absorption
- Absolute bioavailability = 89%
- Distribution
- * 10 L
- Metabolism
- Meloxicam is almost completely metabolized into inactive metabolites by the cytochrome P450 (CYP450) isozymes. CYP2C9 is primarily responsible for metabolism of meloxicam while CYP3A4 plays a minor role. An intermediate metabolite, 5'-hydroxymethyl meloxicam, is further metabolized to 5'-carboxy meloxicam, the major metabolite. Peroxidase activity is thought to produce the two other inactive metabolites of meloxicam.
- Elimination
Clearance
* 8.8 mL/min [Healthy Male Adults (Fed) oral 7.5 mg tablets] * 9.9 mL/min [Eldery Male (Fed) oral 15 mg capsules] * 5.1 mL/min [Eldery Female (Fed) oral 15 mg capsules] * 19 mL/min [Renal Failure (Fasted) oral 15 mg capsules] * 11 mL/min [Hepatic Insufficiency (Fasted) oral 15 mg capsules]
Toxicity
LD50, Acute: 84 mg/kg (Rat); Oral 470 mg/kg (Mouse); Oral 320 mg/kg (Rabbit)
Active Ingredient/Synonyms
Méloxicam | Meloxicam | Meloxicamum | UNII-vg2qf83cgl | Meloxicam |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.